Ophthalmic surgery, lasers & imaging retina · 2015
Dexamethasone intravitreal implant for pseudophakic cystoid macular edema in patients with diabetes.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khurana Rahul N, Palmer James D, Porco Travis C, Wieland Mark R
Аннотация
BACKGROUND AND OBJECTIVE: Diabetic patients are at a higher risk of developing pseudophakic cystoid macular edema (PCME) after cataract surgery. This study evaluated the effect of dexamethasone intravitreal implant (DEX Implant 0.7 mg, Ozurdex; Allergan, Irvine, CA) in diabetic patients with PCME.
PATIENTS AND METHODS: In this prospective case series, six patients with diabetes who developed PCME despite topical anti-inflammatory therapy were treated with a single dexamethasone implant. Outcome measures included best corrected visual acuity (BCVA) and central subfoveal thickness.
RESULTS: The mean increase in BCVA from baseline to day 180 was 14 letters (P = .03); four of six patients (67%) achieved greater than 10-letter improvement in BCVA. The mean decrease in central subfoveal thickness was 100 µm (P < .01 vs baseline) by day 30 and 72 µm by day 180 (P = .004).
CONCLUSIONS: A dexamethasone implant may be an effective treatment for diabetic patients who develop pseudophakic cystoid macular edema after cataract surgery.
PATIENTS AND METHODS: In this prospective case series, six patients with diabetes who developed PCME despite topical anti-inflammatory therapy were treated with a single dexamethasone implant. Outcome measures included best corrected visual acuity (BCVA) and central subfoveal thickness.
RESULTS: The mean increase in BCVA from baseline to day 180 was 14 letters (P = .03); four of six patients (67%) achieved greater than 10-letter improvement in BCVA. The mean decrease in central subfoveal thickness was 100 µm (P < .01 vs baseline) by day 30 and 72 µm by day 180 (P = .004).
CONCLUSIONS: A dexamethasone implant may be an effective treatment for diabetic patients who develop pseudophakic cystoid macular edema after cataract surgery.
Предметные рубрики MeSH
AgedDexamethasoneDiabetes ComplicationsDiabetic RetinopathyDrug ImplantsFemaleFluorescein AngiographyGlucocorticoidsHumansIntraocular PressureLens Implantation, IntraocularMacular EdemaMaleMiddle AgedPhacoemulsificationProspective StudiesPseudophakiaTomography, Optical CoherenceVisual AcuityVitreous Body